COMMUNIQUÉS West-GlobeNewswire

DESCRIPTIF DU PROGRAMME DE RACHAT D’ACTIONS AUTORISE PAR L'ASSEMBLEE GENERALE ORDINAIRE DU 20 JUIN 2024

21/06/2024 - 22:05

Daix, le 21 juin 2024 En application de l'article 241-2 du Règlement Général de l’Autorité des marchés financiers (AMF), le présent descriptif a pour finalité de présenter les objectifs ainsi que les modalités du [...]

Singular Genomics Announces 1-for-30 Reverse Stock Split

21/06/2024 - 22:05

SAN DIEGO, June 21, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and [...]

On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development

21/06/2024 - 22:04

TORONTO and HAIFA, Israel, June 21, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “ Company ” or “ NurExone ”), a pioneering biopharmaceutical company, welcomes Dr. [...]

Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

21/06/2024 - 22:01

WORCESTER, Mass., June 21, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell [...]

Inteleos’ Point-of-Care Ultrasound Certification Academy Launches Comprehensive Maternal Fetal Health Certification

21/06/2024 - 22:00

New OB 2nd/3rd Trimester Certificate Now Available, Completes Suite of Maternal Fetal Health Certification Products ROCKVILLE, Md., June 21, 2024 (GLOBE NEWSWIRE) -- Inteleos, a global non-profit healthcare [...]

Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024

21/06/2024 - 22:00

Daix (France), Long Island City (New York, United States), on June 21, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral [...]

Résultats des votes de l’Assemblée Générale Mixte des actionnaires réunies le 20 juin 2024

21/06/2024 - 22:00

Daix (France), Long Island City (New York, Etats-Unis), le 21 juin 2024 – Inventiva (Euronext Paris et Nasdaq : IVA) (la « Société »), société biopharmaceutique spécialisée dans le développement clinique de petites [...]

HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda

21/06/2024 - 22:00

— Approval for previously treated metastatic colorectal cancer based on results from positive, global, Phase III FRESCO-2 Trial — — FRUZAQLA ® (fruquintinib) is the first novel targeted therapy in the EU for metastatic [...]

Standards Alliance Awards Inteleos Foundation to Expand Ultrasound Training in Kenya

21/06/2024 - 21:43

ROCKVILLE, Md., June 21, 2024 (GLOBE NEWSWIRE) -- The Inteleos Foundation, a public non-profit organization driving positive health outcomes through education in medical imaging, received a three-year, $180,000 subaward [...]

Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH)

21/06/2024 - 19:00

Results from a radiographic study describing skeletal features of pediatric patients with ENPP1 Deficiency will be presented BOSTON, June 21, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” [...]

ALK upgrades its full-year revenue and earnings outlook

21/06/2024 - 18:43

ALK ( ALKB:DC / OMX: ALK B / AKBLF ) today announced that the full-year financial outlook has been upgraded to reflect better than expected sales performance in Q2 and an improved outlook for the remainder of the year. [...]

ALK provides update on regulatory process for the house dust mite allergy tablet in China

21/06/2024 - 18:38

ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that it has decided to withdraw the Biologic License Application (‘BLA’) for its house dust mite (‘HDM’) sublingual allergy immunotherapy tablet in China. ALK will [...]

BioSenic signs a new subscription agreement for a maximum of EUR 2.1M in convertible bonds

21/06/2024 - 18:00

PRESS RELEASE – PRIVILEGED INFORMATION Mont-Saint-Guibert, Belgium, June 21, 2024 6.00pm CEST – BioSenic (Euronext Brussels and Paris: BIOS) , the clinical stage company specializing in serious autoimmune and [...]

BioSenic signe une nouvelle convention de souscription pour un maximum de 2,1 millions d'euros en obligations convertibles

21/06/2024 - 18:00

COMMUNIQUÉ DE PRESSE – INFORMATION PRIVILÉGIÉE Mont-Saint-Guibert, Belgique, le 21 juin 2024, 18h00 CEST – BIOSENIC (Euronext Bruxelles et Paris : BIOS), la société en phase clinique spécialisée dans les maladies auto- [...]

Psychemedics Unveils Inaugural Insights Report: Revealing Drug Trends Through Hair Testing

21/06/2024 - 16:00

DALLAS, June 21, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for drugs of abuse, proudly presents its inaugural Insights Report. This groundbreaking report offers a [...]

Sharecare enters into definitive agreement to be acquired by Altaris

21/06/2024 - 15:25

Sharecare shareholders to receive $1.43 per share in cash Transaction will deliver significant immediate cash value to stockholders upon closing, best positions Sharecare to continue to deliver exceptional service to [...]

Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General Meeting

21/06/2024 - 15:00

Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General Meeting Halle (Saale) / Munich, Germany, June 21, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon, or the Company [...]

Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences

21/06/2024 - 14:15

– Collaboration advancing Palisade Bio’s precision medicine approach through access to cutting-edge expertise and tools in bioinformatics – Candidate PDE4-related biomarkers overlapping with UC pathophysiology have been [...]

Starton Therapeutics Announces 100% Partial Response or Better in Multiple Myeloma Patients in Interim, Top-line Data from STAR-LLD Phase 1b Clinical Trial

21/06/2024 - 14:05

100% of patients enrolled achieved a partial response or better Milder and less frequent drug-related adverse events were observed compared to those associated with Revlimid ® No grade 3 or greater adverse events in [...]